// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Reductions in absolute neutrophil count with sarilumab resulting in dose delays or dose decreases: effects on efficacy and safety

Jeffrey R Curtis - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Neutropenia

Sarilumab

Long-term efficacy with 5-year-radiographic results and safety of sarilumab in combination with csDMARDs in patients with rheumatoid arthritis

Gerd R Burmester - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Sarilumab

Long-term treatment with sarilumab plus conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs): pooled safety and efficacy with over 4 years’ treatment

Hubert van Hoogstraten - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Sarilumab

Long-term safety with sarilumab plus conventional synthetic disease-modifying antirheumatic drugs and sarilumab monotherapy in rheumatoid arthritis: an integrated analysis with 9,000 patient-years of follow-up

Roy Fleischmann - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Sarilumab

New retinal screening guidelines for hydroxychloroquine: feasibility and outcomes

Tegwen Ecclestone - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

The efficacy and cost savings of switching to a single 1g infusion protocol of biosimilar rituximab for rheumatoid arthritis

Yu Lun Sung - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

Mapping between the American College of Rheumatology 20/50/70 and (change in) Disease Activity Score-28 in rheumatoid arthritis

Nuria C Navarro-Coy - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Safety and efficacy of filgotinib in a phase 3 trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic disease modifying anti-rheumatic drugs

David Walker - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Filgotinib

Janus kinase inhibitors demonstrate effectiveness in a real-world multi-biologic DMARD refractory rheumatoid arthritis population

John Fitton - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Baricitinib

The impact of anxiety on quality of life and disease activity in rheumatoid arthritis: a systematic review

Annabelle R Machin - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Rheumatoid arthritis

N/A

Single centre cohort of refractory rheumatoid arthritis also identifies a rare subgroup of multiple targeted therapy class non-response

John Fitton - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Mechanisms determining disease activity of rheumatoid arthritis in pregnancy: a systematic review

Charles Raine - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

The benefits for acute physicians of onsite rheumatology in a large urban district general hospital

Suma Mahendrakar - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The state of play of adolescent and young adult care in a rheumatology service in a large urban district general hospital

Tahiyyah Akhteruzzaman - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Baricitinib: Sheffield Teaching Hospitals’ experience so far

Ruth Smith - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Baricitinib

Development of an occupational therapy advanced practitioner role within a multidisciplinary early inflammatory arthritis clinic in Salford

Catherine McCoy - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Early inflammatory arthritis

N/A

Service evaluation of one-stop provision of diagnostic ultrasound, drug education and therapy services in an early inflammatory arthritis clinic in Salford

Catherine McCoy - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Early inflammatory arthritis

N/A

The development of a nurse-led capillaroscopy clinic for the Belfast Trust

Ashley A B A Elliott - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Quality improvement to halve non-adherence to methotrexate

Anne Barton - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Methotrexate

Audit of contraception and family planning counselling in female patients commencing methotrexate therapy in a large rheumatology outpatient department

Lauren R Ankrah - British Society for Rheumatology (BSR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Methotrexate

Copyright © 2026. QuantiNova All rights reserved